Delays to an Indian companys generic versions of three blockbuster drugs annually cost US healthcare payers millions of dollarsand preserve millions of dollars in revenue for the makers of the brandname versions  AstraZeneca PLCs heartburn drug Nexium is the most recent big drug to face delays to its generic version Key patents on the UK companys purple pill which ranks among the worlds bestselling prescription drugs expired at the end of May but manufacturing problems at Indias Ranbaxy Laboratories
  